Literature DB >> 2223576

The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.

G J Schuurhuis1, H J Broxterman, H M Pinedo, T H van Heijningen, C K van Kalken, J B Vermorken, E C Spoelstra, J Lankelma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2223576      PMCID： PMC1971481          DOI： 10.1038/bjc.1990.335

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  33 in total

1.  Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells.

Authors:  G J Schuurhuis; H J Broxterman; A Cervantes; T H van Heijningen; J H de Lange; J P Baak; H M Pinedo; J Lankelma
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

Review 2.  A possible role for cyclosporins in cancer chemotherapy.

Authors:  P R Twentyman
Journal:  Anticancer Res       Date:  1988 Sep-Oct       Impact factor: 2.480

3.  Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C.

Authors:  F K Zhao; L F Chuang; M Israel; R Y Chuang
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

Review 4.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

5.  Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

Authors:  W S Dalton; T M Grogan; J A Rybski; R J Scheper; L Richter; J Kailey; H J Broxterman; H M Pinedo; S E Salmon
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

6.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

7.  Immunohistochemical detection of P-glycoprotein in human tumor cells with a low degree of drug resistance.

Authors:  H J Broxterman; H M Pinedo; C M Kuiper; J J van der Hoeven; P de Lange; J J Quak; R J Scheper; H G Keizer; G J Schuurhuis; J Lankelma
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

8.  Role of protein kinase C in phosphorylation of vinculin in adriamycin-resistant HL-60 leukemia cells.

Authors:  A Aquino; K D Hartman; M C Knode; S Grant; K P Huang; C H Niu; R I Glazer
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

9.  Phorbol esters induce multidrug resistance in human breast cancer cells.

Authors:  R L Fine; J Patel; B A Chabner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

Review 10.  The multidrug resistance phenotype.

Authors:  S B Kaye
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640
View more
  13 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.

Authors:  Ake Berglund; Bengt Glimelius; Jonas Bergh; Ola Brodin; Marie-Louise Fjällskog; Hans Hagberg; Anne von Heideman; Rolf Larsson; Bengt Tholander; Manuel de la Torre; Gunnar Aström; Kjell Oberg; Gunnar Parö; Peter Nygren
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 3.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

4.  Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.

Authors:  R G del Moral; M Andujar; C Ramírez; M Gómez-Morales; M Masseroli; M Aguilar; A Olmo; F Arrebola; M Guillén; M J García-Chicano; F F Nogales; F O'Valle
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

Review 5.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Disposition kinetics of taxanes in peritoneal dissemination.

Authors:  Ken'ichi Miyamoto; Tsutomu Shimada; Kazuki Sawamoto; Yoshimichi Sai; Yutaka Yonemura
Journal:  Gastroenterol Res Pract       Date:  2012-05-16       Impact factor: 2.260

7.  Reversal of multidrug resistance by surfactants.

Authors:  D M Woodcock; M E Linsenmeyer; G Chojnowski; A B Kriegler; V Nink; L K Webster; W H Sawyer
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

8.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.

Authors:  G J Schuurhuis; H J Broxterman; J H de Lange; H M Pinedo; T H van Heijningen; C M Kuiper; G L Scheffer; R J Scheper; C K van Kalken; J P Baak
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

9.  Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.

Authors:  G J Schuurhuis; T H van Heijningen; A Cervantes; H M Pinedo; J H de Lange; H G Keizer; H J Broxterman; J P Baak; J Lankelma
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

10.  Effects of Cremophor EL on distribution of Taxol to serum lipoproteins.

Authors:  E Sykes; K Woodburn; D Decker; D Kessel
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.